What is Veracyte's cash & equivalents?

Veracyte (VCYT) reported cash & equivalents of $264.79M in Q1 2026.

How has Veracyte's cash & equivalents changed year-over-year?

Veracyte's cash & equivalents increased by 41.0% year-over-year, from $187.77M to $264.79M.

What is the long-term trend for Veracyte's cash & equivalents?

Over 5 years (2020 to 2025), Veracyte's cash & equivalents has grown at a 0.8% compound annual growth rate (CAGR), from $349.97M to $364.23M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Veracyte VCYT Cash & Equivalents

Cash & Equivalents at other companies

Guardant HealthGH

$1.1B+37.0%

Natera, Inc.NTRA

$1.09B+11.7%

Bio-Rad LaboratoriesBIO

$509M-2.7%

RevvityRVTY

$861.47M-24.3%

Labcorp HoldingsLH

$981.1M+166%

Quest DiagnosticsDGX

$393M+109%

Other financials

Income statement

See full

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

See full

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

See full

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

See full

Market cap$4.28B+10.7%

Enterprise value$4.05B+7.4%

P/E48.6×-68.3×

P/S7.9×-0.4×

Profitability

See full

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

See full

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veracyte's cash & equivalents?: Veracyte (VCYT) reported cash & equivalents of $264.79M in Q1 2026.
How has Veracyte's cash & equivalents changed year-over-year?: Veracyte's cash & equivalents increased by 41.0% year-over-year, from $187.77M to $264.79M.
What is the long-term trend for Veracyte's cash & equivalents?: Over 5 years (2020 to 2025), Veracyte's cash & equivalents has grown at a 0.8% compound annual growth rate (CAGR), from $349.97M to $364.23M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.